AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

MarketsPricingSign inSign up free

GEFITINIB

6 registrations across 6 African markets— 4 active

Markets with GEFITINIB

🇲🇦Morocco
1 registration
1 active
🇲🇼Malawi
1 registration
0 active
🇹🇳Tunisia
1 registration
0 active
🇹🇿Tanzania
1 registration
1 active
🇿🇦South Africa
1 registration
1 active
🇿🇼Zimbabwe
1 registration
1 active

Recent registrations

Brand / ProductMarketHolderStatusExpires
GEFITINIB
TABLET, COATED; ORAL
🇿🇼ZimbabweCIPLA LTDactiveDec 2027
IRESSA
Comprimé pelliculé / 250 mg
🇹🇳TunisiaAstraZeneca AB SUEDEexpiredApr 2016
GEFITINIB 250MG COATED TABLET
COATED TABLET
🇲🇼Malawi—expiredJun 2012
GEFIRIX🇿🇦South AfricaEurolab (Pty) LtdactiveJan 1900
IRESSA 250 MG
COMPRIME PELLICULE
🇲🇦Morocco—active—
Gefitinib Tablets
Tablets
🇹🇿TanzaniaCipla Limitedactive—

GEFITINIB in Africa — Regulatory Overview

GEFITINIB is registered across 6 African markets with 6 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Morocco, Malawi, Tunisia, Tanzania and 2 more. AfricaRegulatory refreshes this data daily from official government sources.

Of the 6 registrations, 4 (67%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.